FDA
-
-
-
-
-
-
-
Pulmatrix (PULM) Reports Q1, Announces Divestment Plan for Assets
-
-
-
-
-
-
-
Pulmatrix (PULM) Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine
-
-
-
-
-
-
-
Pulmatrix (PULM) Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine
-
-
-
-
-
-
-
Pulmatrix (PULM) Reports Q1 Revenue of $1.2M, EPS of ($1.51)
-
-
-
-
-
-
-
Pulmatrix Announces Resolution of Contract Dispute with Cipla
-
-
-
-
-
-
-
Pulmatrix Reports Q1 2020 Results
-
-
-
-
-
-
-
Pulmatrix Enters Into Binding Term Sheet with Cipla Technologies LLC for the Development and Commercialization of Pulmazole
-
322,242 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

